NCT04243863View on ClinicalTrials.gov

VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

April 5, 2021

Study Completion Date

April 5, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

VNRX-7145

Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)

DRUG

Placebo

Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)

Trial Locations (1)

78217

Worldwide Clinical Trials Early Phase Services, LLC, San Antonio

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Venatorx Pharmaceuticals, Inc.

INDUSTRY

NCT04243863 - VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter